Investigational drug · Phase 3
SB27
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-small Cell Lung Cancer Stage IV.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
60
Any phase or sponsor naming "SB27"
First trial start
2024
Mar 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SB27", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer Stage IV
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SB27" as an intervention, largest first.
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT02506153 · 1,301 participants · Start Nov 10, 2015 · Primary completion Sep 15, 2023
Drug: Ipilimumab; Pembrolizumab and 1 more · For: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Cutaneous Melanoma and 6 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 576 sites in all
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Pivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT04267848 · 1,210 participants (planned) · Start Jun 16, 2020 · Primary completion Jan 31, 2030
Drug: Carboplatin; Cisplatin and 4 more · For: Lung Non-Small Cell Carcinoma; Lung Non-Small Cell Squamous Carcinoma; Lung Non-Squamous Non-Small Cell Carcinoma and 3 more
Sites: Anchorage, Alaska; Fairbanks, Alaska; Gilbert, Arizona · 1,151 sites in all
- Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT02954874 · 1,195 participants · Start Jan 18, 2017 · Primary completion Aug 3, 2026
Drug: Pembrolizumab · For: Breast Carcinoma In Situ; Invasive Breast Carcinoma; Stage I Breast Cancer AJCC v7 and 3 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 919 sites in all
- Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial CancerPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914612 · 813 participants · Start Aug 22, 2019 · Primary completion Dec 16, 2022
Drug: Carboplatin; Paclitaxel and 1 more · For: Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Endometrioid Adenocarcinoma and 13 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Goodyear, Arizona · 397 sites in all
- Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial CancerPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03244384 · 739 participants (planned) · Start Nov 3, 2017 · Primary completion Jan 1, 2027
Drug: Pembrolizumab · For: Localized Renal Pelvis and Ureter Urothelial Carcinoma; Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma and 8 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 914 sites in all
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT07383441 · 718 participants (planned) · Start Jun 5, 2026 · Primary completion Jan 31, 2033
Drug: Axitinib; Cabozantinib and 7 more · For: Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8 and 1 more
Sites: Fayetteville, Arkansas; Jonesboro, Arkansas; Rogers, Arkansas · 41 sites in all
- Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung CancerPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03793179 · 600 participants (planned) · Start Apr 5, 2019 · Primary completion Sep 30, 2027
Drug: Carboplatin; Pembrolizumab and 1 more · For: Lung Non-Squamous Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8 and 1 more
Sites: Mobile, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,094 sites in all
- A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung CancerPivotal-lookingActive, not recruiting
Samsung Bioepis Co., Ltd.Industry
NCT06348199 · 555 participants · Start Mar 12, 2024 · Primary completion Mar 10, 2026
Drug: SB27; Keytruda · For: Non-small Cell Lung Cancer Stage IV
Sites: Banja Luka, Bosnia and Herzegovina; Mostar, Bosnia and Herzegovina; Sarajevo, Bosnia and Herzegovina · 93 sites in all
- Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell CarcinomaPivotal-lookingNot yet recruiting
National Cancer Institute (NCI)NIH
NCT07689240 · 400 participants (planned) · Start Feb 10, 2027 · Primary completion Jan 1, 2032
Drug: Pembrolizumab · For: Non-Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
Newest research
PubMed records naming it or its code names, newest first.
- Polydopamine-chitosan coated biofilm-state Lacticaseibacillus paracasei SB27 as a living band-aid for targeted colitis therapy.
Liu Y, Liu Y, Jiang L, et al. · Mater Today Bio 2025
- Assessing the potential impacts of California Senate Bill 27 (SB27) on the antimicrobial susceptibility of Escherichia coli from raw meat.
Quinlivan V, Park DE, Aziz M, et al. · Environ Health Perspect 2025
- Limitations of Reporting Requirements under California's Livestock Antimicrobial Restriction Law.
Quaade S, Casey JA, Nachman KE, et al. · Environ Health Perspect 2024
- Polysaccharide of Lactobacillus casei SB27 reduced colon cancer cell prognosis through mitochondrial damage by upregulation of HINT2.
Di W, Li X, Yang Q · Asia Pac J Clin Oncol 2023
- Impact of California's Senate Bill 27 on Antimicrobial-Resistant Escherichia coli Urinary Tract Infection in Humans: Protocol for a Study of Methods and Baseline Data.
Florea A, Casey JA, Nachman K, et al. · JMIR Res Protoc 2023
- Impact of a Statewide Livestock Antibiotic Use Policy on Resistance in Human Urine Escherichia coli Isolates: A Synthetic Control Analysis.
Casey JA, Tartof SY, Davis MF, et al. · Environ Health Perspect 2023
Also in development for Non-small Cell Lung Cancer Stage IV
- Olvi-Vecolvimulogene nanivacirepvec, GL-ONCPhase 33 trials
Genelux Corporation · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer
Genelux Corporation · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.